arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BIOMARIN PHARMACEUTICAL INC

BMRN
$56.12 ▼ -1.01 (-1.77%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Neutral
auto_awesome

Analytical Summary

BIOMARIN PHARMACEUTICAL INC shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $10.8B
Dividend Yield —
Revenue Growth 12.9% ↘
Op. Margin 12.7% ↘
ROIC 4.9% ↘
FCF / Share $3.78 ↗
Trailing P/E 30.8x
Price / Book 1.8x
FCF Yield 6.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.22B
↑ +12.9% —
Net Income Profit after all expenses
$348.90M
↓ -18.3% —
Operating Margin Operating profit as % of sales
12.7%
↓ -25.1% 63th
FCF / Share Free cash flow per share
$3.78
↑ +47.4% —

Health Breakdown

Profitability ↑
71
Returns
55
Financial Health
94
Cash Quality
87

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 73 quarters